APA (7th ed.) Citation

Lasagna, A., Cassaniti, I., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., . . . Pedrazzoli, P. (2022). Humoral and cell-mediated immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with cancer on active treatment: Focus on wild type, Delta and Omicron strains. Journal of clinical oncology, 40(16_suppl), e13505. https://doi.org/10.1200/JCO.2022.40.16_suppl.e13505

Chicago Style (17th ed.) Citation

Lasagna, Angioletta, et al. "Humoral and Cell-mediated Immune Response to the Third Dose of BNT162b2 Anti-SARS-CoV-2 Vaccine in Patients with Cancer on Active Treatment: Focus on Wild Type, Delta and Omicron Strains." Journal of Clinical Oncology 40, no. 16_suppl (2022): e13505. https://doi.org/10.1200/JCO.2022.40.16_suppl.e13505.

MLA (9th ed.) Citation

Lasagna, Angioletta, et al. "Humoral and Cell-mediated Immune Response to the Third Dose of BNT162b2 Anti-SARS-CoV-2 Vaccine in Patients with Cancer on Active Treatment: Focus on Wild Type, Delta and Omicron Strains." Journal of Clinical Oncology, vol. 40, no. 16_suppl, 2022, p. e13505, https://doi.org/10.1200/JCO.2022.40.16_suppl.e13505.